Biotech for less than a buck. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who wrote (535)	4/20/2000 9:11:00 AM
From: Toni Wheeler	Read Replies (1) of 743

News for GNLB... siliconinvestor.com Genelabs Discloses Discovery of a Novel Class of Antiviral Compounds From Its RNA-Binding Proprietary Technology <<<REDWOOD CITY, Calif., April 20 /PRNewswire/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) reported today the discovery, utilizing its proprietary technology, and the characterization of a novel class of small molecules synthesized by the company that have inhibitory activity against several RNA viruses. James A.D. Smith, President and Chief Executive Officer said, "RNA viruses have been elusive targets for drug discovery and represent an area of significant medical need. They include some of the most pernicious viruses such as hepatitis C (HCV), yellow fever, Dengue and West Nile virus to name a few. We are extremely pleased that our RNA-binding drug discovery program has produced a novel class of compounds that display potentially broad-spectrum antiviral activity." ...>>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next